Mosapride
As of the edition of 20 October 2026, Mosapride is a small molecule: in active development; acts on HTR3A, HTR3B and HTR3C and 3 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2025
- Kind
- Small molecule
- Registered trials
- 17, 2 stopped early
- Disease areas
- Digestive system; Cancer; Ear, nose and throat; Heart and blood vessels; Hormones; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 6 | 2 | 1 | 1 |
| Phase 1 | 3 | 2 | 0 | 0 |
| Phase 2 | 2 | 0 | 1 | 0 |
| Phase 3 | 2 | 1 | 0 | 1 |
| Phase 4 | 4 | 1 | 0 | 0 |
| All trials | 17 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| IlDong Pharmaceutical | Lead sponsor of trials | 2013 to now |
| GSK | Lead sponsor of trials | 2014 to now |
| Shandong New Time Pharmaceutical | Lead sponsor of trials | 2024 to now |